Podcasts about Vertex Pharmaceuticals

Is memory truly cyclical, or has the AI data center boom changed the rules? In Part 2 of the How CSI Invests series, Nick and Kasey tackle one of the most debated questions among semiconductor investors by walking through the investment thesis checklist step that asks: what kind of business cycle does this company actually have?Rather than labeling companies simply cyclical or non-cyclical, the framework breaks businesses into short cycle, long cycle, and non-cyclical categories based on how closely revenue tracks changes in GDP growth. A short cycle business sees revenue move quickly with the economy, while a long cycle or non-cyclical business continues growing steadily regardless of macro conditions. The traditional eleven sectors of the economy do not map cleanly onto this framework, and Nick and Kasey explain why semiconductors, SaaS, telecom carriers, and ad-driven internet platforms can all fall in very different places even within the same official sector.The episode applies this framework to six real companies. Micron is examined as a short cycle business currently in year two of a strong memory upcycle, with historical precedent for these cycles to run several years. Intuitive Surgical is discussed as a long cycle healthcare hardware business tied to product generation launches. Vertex Pharmaceuticals is presented as a genuinely non-cyclical pharmaceutical company with steady growth. NextEra Energy represents the utilities sector and one of the longest cycles of all. Credo Technologies, a newer public company, is evaluated as likely short cycle, with a look at its fiscal 2027 guidance calling for eighty percent revenue growth and fifty percent adjusted profit margins. Finally, Palo Alto Networks is broken down as a cyclical business once acquisitions like CyberArk and Chronosphere are stripped out, with commentary on CEO Nikesh Arora's view that cybersecurity is constantly chasing the next emerging risk.The episode closes with the revenue analysis questions CSI uses for every company: who the primary customers are, whether revenue is concentrated, what is actually being monetized, why customers choose to spend money with that company over alternatives, and what risks could disrupt the business. Understanding these fundamentals is what allows an investor to tune out noisy debates about whether a cycle has "changed forever" and instead build real conviction in a business.For in-depth stock research and the Semiconductor Insider membership,visit chipstockinvestor.com.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries is one of constant evolution, characterized by scientific advancements, strategic mergers, and regulatory maneuvers that shape the future of healthcare. In a significant scientific breakthrough, Merck & Co. and Gilead Sciences have made strides in HIV treatment with the development of a weekly pill. This innovative regimen combines Merck's islatravir with Gilead's lenacapavir, showing promise in two phase 3 trials. If approved, this long-acting oral therapy could revolutionize HIV care by offering a more convenient dosing schedule, potentially improving patient adherence and outcomes substantially. This novel regimen signifies progress towards simplifying HIV treatments with once-weekly dosing. Meanwhile, in the oncology sector, Gilead's Trodelvy faced challenges when combined with Merck's Keytruda as a first-line treatment for PD-L1-high non-small cell lung cancer. The phase 3 EVOKE-03 trial was terminated, shifting attention to competitors like AstraZeneca and Daiichi Sankyo, who continue to advance their own therapies in this area. In a strategic move to bolster its position in lung cancer treatment, GlaxoSmithKline (GSK) is acquiring Nuvalent for $10.6 billion, aiming to secure near-approval cancer therapies capable of challenging market leaders like Roche and Pfizer. This acquisition underscores the focus on targeted cancer therapies that increase treatment efficacy by honing in on specific genetic markers. Nuvalent's innovative pipeline of small molecule inhibitors targets drug resistance and mutations in cancer treatment—a strategic addition to GSK's portfolio aimed at enhancing its position amidst rapid advancements and intense competition in oncology. In diabetes and obesity management, Eli Lilly is advancing with its new oral GLP-1 receptor agonist, Foundayo (orforglipron), which has shown competitive efficacy over oral semaglutide. Analysts see Lilly's progress as strengthening its leadership in the growing obesity drug market. Similarly, AstraZeneca is making progress with its own GLP-1 candidate, elecoglipron, as phase 2 data sets the stage for pivotal studies. Promising clinical trial data from Eli Lilly's retatrutide for obesity-related conditions and AstraZeneca's elecoglipron suggest a strengthening pipeline for GLP-1 receptor agonists known for their dual effects on weight management and glycemic control. On the diagnostics front, Roche reaffirms its €600 million investment in Germany amid industry retrenchments by companies like Eli Lilly and Boehringer Ingelheim. However, Roche remains cautious about future risks due to shifting economic conditions. The financial dynamics within biotech are also noteworthy. Parabilis Medicines is planning a potentially record-setting IPO following Kailera Therapeutics' successful public offering earlier this year. These trends indicate strong investor confidence and an influx of funding towards innovative cancer therapies. Meanwhile, CeQur's $100 million Series E funding round aims at accelerating insulin patch delivery systems' commercial growth—highlighting ongoing innovation in diabetes management solutions. Regulatory updates reveal AstraZeneca facing reprimands from the UK marketing watchdog due to repeated breaches related to LinkedIn activities—an ongoing challenge in pharmaceutical marketing compliance. The integration of digital health solutions continues apace as ixlayer partners with Vertex Pharmaceuticals to launch a digital acute pain management platform. This initiative aims at improving patient care by reducing reliance on opioid-based treatments. These developments paint a picture of an industry where scientific innovations, regulatory hurdles, and technological advancements intersect to shape future therapeutic landscapes. Precision oncology is another area witnessing substantial growth. The landscape also sees notable activity in rare disease therapeutics. Johnson & Johnson's Talvey has gained acceptance in Scotland for treating relapsed multiple myeloma using bispecific antibody technology—a trend toward leveraging immune system targeting technologies to enhance cancer treatment efficacy. Moreover, Zai Lab's Tivdak received approval from China's NMPA for cervical cancer treatment based on Phase 3 data, highlighting the rise of antibody-drug conjugates (ADCs) as potent oncology therapies due to their targeted delivery mechanisms. On the research collaboration front, AlzeCure Pharma's partnership with Eli Lilly focuses on Alzheimer's disease research through Alzstatin ACD680—a small molecule targeting neurodegenerative pathways—a testament to the collaborative efforts needed to tackle complex diseases like Alzheimer's. However, challenges persist as Bial discontinued its GCase activator program after failing Phase 2b trials for Parkinson's patients with GBA1 variants—a stark reminder of the high-risk nature inherent in drug development despite initial promise. These myriad developments underscore a vibrant period within pharmaceutical and biotech sectors where scientific advancements rapidly translate into actionable therapies promising substantial improvements in patient care by addressing unmet medical needs globally.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's episode dives into the ever-evolving landscape of the pharmaceutical and biotechnology industries, which are experiencing significant transformations driven by scientific advancements, strategic realignments, and regulatory changes. Sanofi is making a significant move by investing $294 million to expand its AI center of excellence in Toronto. This investment is part of a broader trend in the sector to optimize pharmaceutical operations and accelerate drug development through digital transformation. By enhancing its AI capabilities, Sanofi aims to streamline processes and reduce time-to-market for new drugs, positioning itself as a leader in this digital era. In clinical trials, Cytokinetics has reported a pivotal success with MyoKardia's drug Myqorzo in a Phase 3 trial aimed at treating non-obstructive hypertrophic cardiomyopathy. If approved, Myqorzo would be the first treatment available for this condition, highlighting ongoing efforts within the industry to address unmet medical needs with innovative therapies. However, not all ventures meet expectations. Pfizer's acquisition of Trillium Therapeutics for $2.3 billion did not materialize as hoped, leading to the discontinuation of its remaining clinical-stage candidates. This outcome underscores the risks inherent in pharmaceutical investments and the importance of thorough evaluation of potential therapeutic candidates. Similarly, Vertex Pharmaceuticals encountered challenges with its inhaled cystic fibrosis candidate developed with Moderna due to tolerability issues, highlighting patient safety's role in clinical trials. Strategic shifts are also taking place in workforce management. BioNTech plans to cut 1,860 jobs as it exits manufacturing sites in Germany and Singapore, reflecting broader industry trends toward operational optimization. Similarly, Novartis is closing its manufacturing site in Wehr, Germany, resulting in 220 job cuts as part of efforts to streamline operations. Regulatory developments continue to shape industry dynamics. Axsome Therapeutics received FDA approval for Auvelity as a treatment for agitation associated with Alzheimer's disease. This not only enhances Axsome's market potential but also underscores the critical role of regulatory agencies in facilitating access to treatments for complex conditions. Moreover, CAR-T therapies are expanding beyond oncology into autoimmune diseases. Kyverna Therapeutics is advancing toward a groundbreaking approval for CAR-T therapy in autoimmune disorders, marking an evolution in therapeutic applications. The recent developments underscore a dynamic phase characterized by technological innovation and strategic restructuring. AI technologies are revolutionizing drug discovery processes while successful clinical trials expand treatment options for previously unmet needs. Yet challenges remain with investment risks and organizational realignments reshaping operational strategies. Pfizer's discontinuation of its investment in Trillium Therapeutics due to inadequate clinical results emphasizes the necessity for robust data to support therapeutic viability. On a regulatory front, Strand Therapeutics stresses reforming the FDA's Investigational New Drug process to maintain U.S. leadership in biomedical innovation amid global competition. Passage Bio's strategic review following regulatory setbacks with its gene therapy program further exemplifies biotechnological unpredictability. Viridian Therapeutics' success with its anti-IGF-1R antibody bodes well for FDA approval and competition against established players like Amgen. The formation of the American Biotech Innovation Alliance signifies efforts to unify domestic biotech strategies amid global competition. Investments continue despite these challenSupport the show

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WYB865. CME/NCPD/AAPA credit will be available until April 12, 2027.Transformative Care for Hemoglobinopathies: Guidance on the Gene Therapy Experience in SCD & Thalassemia In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Beam Therapeutics and Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WYB865. CME/NCPD/AAPA credit will be available until April 12, 2027.Transformative Care for Hemoglobinopathies: Guidance on the Gene Therapy Experience in SCD & Thalassemia In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Beam Therapeutics and Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WYB865. CME/NCPD/AAPA credit will be available until April 12, 2027.Transformative Care for Hemoglobinopathies: Guidance on the Gene Therapy Experience in SCD & Thalassemia In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Beam Therapeutics and Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WYB865. CME/NCPD/AAPA credit will be available until April 12, 2027.Transformative Care for Hemoglobinopathies: Guidance on the Gene Therapy Experience in SCD & Thalassemia In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Beam Therapeutics and Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WYB865. CME/NCPD/AAPA credit will be available until April 12, 2027.Transformative Care for Hemoglobinopathies: Guidance on the Gene Therapy Experience in SCD & Thalassemia In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Beam Therapeutics and Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WYB865. CME/NCPD/AAPA credit will be available until April 12, 2027.Transformative Care for Hemoglobinopathies: Guidance on the Gene Therapy Experience in SCD & Thalassemia In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Beam Therapeutics and Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WYB865. CME/NCPD/AAPA credit will be available until April 12, 2027.Transformative Care for Hemoglobinopathies: Guidance on the Gene Therapy Experience in SCD & Thalassemia In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Beam Therapeutics and Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WYB865. CME/NCPD/AAPA credit will be available until April 12, 2027.Transformative Care for Hemoglobinopathies: Guidance on the Gene Therapy Experience in SCD & Thalassemia In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Beam Therapeutics and Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WYB865. CME/NCPD/AAPA credit will be available until April 12, 2027.Transformative Care for Hemoglobinopathies: Guidance on the Gene Therapy Experience in SCD & Thalassemia In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Beam Therapeutics and Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WYB865. CME/NCPD/AAPA credit will be available until April 12, 2027.Transformative Care for Hemoglobinopathies: Guidance on the Gene Therapy Experience in SCD & Thalassemia In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Beam Therapeutics and Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant advancements and strategic moves shaping the ever-evolving landscape of drug development and patient care. The U.S. Food and Drug Administration, under Commissioner Marty Makary, is pursuing a comprehensive policy agenda as revealed in the fiscal year 2027 budget proposal to Congress. This agenda proposes a new clinical trial initiation pathway alongside enhanced enforcement powers. These initiatives are designed to streamline drug development processes while ensuring compliance with advertising standards. The implications are clear—a potential shift towards more rigorous oversight and innovation facilitation in clinical trials, which could redefine how new therapies reach the market. In line with these regulatory developments, the FDA is also advocating for expanded authority to combat misleading direct-to-consumer drug advertisements. This aligns with broader efforts to enhance consumer protection and ensure transparency within pharmaceutical marketing practices. In the realm of oncology, Gilead Sciences has underscored its strategic focus by acquiring Tubulis for a substantial $3.15 billion upfront, with additional milestone payments potentially raising the total to $5 billion. This acquisition highlights Gilead's commitment to antibody-drug conjugates (ADCs), a critical advancement in targeted cancer therapy. ADCs offer the ability to deliver cytotoxic agents directly to tumor cells, minimizing systemic exposure and potentially enhancing treatment outcomes for oncology patients. Similarly focused on oncology innovations, Stipple Bio has emerged with a $100 million Series A funding round to develop tumor-specific epitope-targeting ADCs. This approach combines the specificity of antibodies with the cytotoxic potency of drugs, signaling a promising direction for minimizing off-target effects and enhancing therapeutic efficacy in cancer treatments. Meanwhile, ImmunityBio has responded proactively to FDA scrutiny regarding promotional claims about its bladder cancer drug, Anktiva. The FDA's warning on "false or misleading" claims prompted ImmunityBio to implement new compliance protocols. This situation underscores the critical importance of accurate communication on drug efficacy and safety and highlights the role of regulatory bodies in maintaining public trust. Vertex Pharmaceuticals is making strides by leveraging advancements in drug delivery technologies through a partnership with Halozyme Therapeutics and its newly acquired Elektrofi technology. This $15 million deal is aimed at improving drug delivery mechanisms, potentially enhancing patient adherence and therapeutic outcomes through more efficient administration routes. In other corporate maneuvers, Neurocrine Biosciences has acquired Soleno Therapeutics for $2.9 billion, gaining access to Vykat XR, a promising treatment for a rare obesity disorder. Such acquisitions highlight an industry trend toward specialized treatments that address niche medical needs, reflecting a strategic shift towards consolidating expertise and resources. In terms of clinical advancements, Amgen's recent success with subcutaneous Tepezza in Phase 3 trials marks a significant milestone in thyroid eye disease treatment. Offering a more patient-friendly subcutaneous administration, this development holds promise for improving treatment adherence and quality of life for patients with autoimmune diseases. The application of artificial intelligence in drug design is also making waves, exemplified by AI models identifying a novel treatment candidate for opioid addiction. This compound has shown efficacy in reducing fentanyl cravings in preclinical models—an encouraging sign for addressing the opioid crisis through advanced therapeutic modaSupport the show

Halozyme Therapeutics and Vertex Pharmaceuticals have entered a partnership to license Halozyme's Hypercon technology, involving a $15 million upfront payment and potential future milestones. Vertex will use the technology for up to three drug targets. Hypercon aims to reduce injection volumes, facilitating at-home drug administration. Halozyme will receive royalties on sales of products developed with Hypercon. This collaboration enhances Halozyme's drug delivery portfolio, which includes Enhanze technology, already licensed to major pharmaceutical companies.Learn more on this news by visiting us at: https://greyjournal.net/news/ Hosted on Acast. See acast.com/privacy for more information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries is undergoing substantial shifts, marked by leadership changes, regulatory updates, scientific breakthroughs, and strategic expansions.A significant development involves BioNTech's CEO Ugur Sahin and CMO Ozlem Tureci departing to establish a new company focused on next-generation mRNA technologies. This move has sparked discussions about BioNTech's future trajectory without its founders' guidance, considering their pivotal role in developing the COVID-19 vaccine. Analysts are concerned about BioNTech's ability to continue innovating and expanding its mRNA platform independently. As they transition roles, BioNTech is steering towards becoming a multiproduct commercial biotech entity, potentially diversifying its pipeline beyond vaccines towards broader therapeutic applications.In regulatory news, Novo Nordisk's U.S. headquarters recently received a warning letter from the FDA following an inspection, highlighting ongoing compliance challenges. This situation underscores the critical importance of maintaining rigorous quality standards in pharmaceutical manufacturing to avoid regulatory setbacks. Meanwhile, Novo Nordisk has partnered with Hims & Hers to distribute GLP-1 drugs Ozempic and Wegovy targeting diabetes management—a move resolving previous legal disputes while emphasizing digital health integrations into traditional pharmaceutical frameworks.On a more positive note, the FDA has approved leucovorin for an ultra-rare subset of cerebral folate deficiency without requiring clinical trials. This decision might suggest a shift towards more flexible regulatory pathways for rare diseases, potentially accelerating treatments for patients with unmet medical needs. The FDA is also working on its fourth revision of draft guidance on biosimilar testing requirements to streamline the approval process for these cost-effective alternatives to biologic drugs, thereby reducing barriers to market entry and fostering competition.In scientific advancements, Vertex Pharmaceuticals reported positive Phase 3 results for povetacicept, a kidney disease treatment poised for expedited FDA approval. This underscores ongoing innovation in addressing chronic conditions with high unmet needs. Vertex is advancing with a rolling biologics license application supported by late-stage data from the RAINIER study, aiming to address unmet medical needs within chronic kidney disease management.Meanwhile, researchers at Emory University are exploring artificial intelligence as a tool to detect heart disease through breast mammogram screenings, potentially revolutionizing cardiovascular risk assessment by integrating AI into routine diagnostics.CSL is investing $1.5 billion in a plasma-based medicine facility near Chicago, marking a strategic expansion aimed at enhancing production capacity for plasma-derived therapies. This move aligns with growing global demand for plasma products and underscores CSL's commitment to scaling operations to meet patient needs.Turning to other industry trends, Breakout Ventures has announced a $114 million fund dedicated to companies integrating artificial intelligence with scientific endeavors. This investment highlights the transformative potential of AI in accelerating drug discovery and optimizing research processes.Political scrutiny over the FDA's handling of rare disease drug approvals is intensifying. Senator Ron Johnson has launched an investigation into recent rejections, signaling potential future changes in how regulatory agencies balance innovation with safety and efficacy standards.The cell and gene therapy sectors are experiencing robust growth prospects. Recent analysis projects that this market will skyrocket to $146 billion by 2032, reflecting increasing investments and advSupport the show

Advances in genetics have transformed how we understand kidney disease, and the discovery of APOL1 has been a major milestone. In this episode of Kidney Commute: Pitstop, host Dr. Osama El Shamy is joined by Meyeon Park, MD, MAS and Denay Richards, PhD to explore the role of APOL1 genetic variants in kidney disease development and progression. The discussion covers the epidemiology of APOL1, the interplay between genetic risk and environmental factors, and scenarios in which APOL1 genetic testing may be considered. Speakers also address how test results are communicated to patients and families, implications for disease management, emerging research into APOL1 targeted therapies, and the significance of newly introduced ICD 10 codes for APOL1 mediated kidney disease. After listening to the podcast, please complete the survey at https://kidneyforms.tfaforms.net/4728148. This educational episode is supported by Vertex Pharmaceuticals.

Administrative Law: May a company offer fertility support services to those on government insurance programs, where its products cause fertility issues, without violating anti-kickback prohibitions? - Argued: Mon, 23 Feb 2026 11:57:56 EDT

Vertex Pharmaceuticals Incorporated v. HHS

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events shaping the landscape of drug development, regulatory scrutiny, and industry advancement. As we navigate this complex terrain, we'll explore how these changes impact both companies and patients.In recent news, Moderna has encountered a substantial hurdle as the FDA declined to review its flu vaccine candidate, mRNA-1010. This decision marks a notable shift from the expedited processes witnessed during the COVID-19 pandemic, reflecting a more cautious regulatory approach under current administrative leadership. Analysts suggest this could indicate broader regulatory changes that might affect future vaccine approvals. Moderna's situation is emblematic of the challenges companies face in maintaining momentum post-pandemic, especially as their research and development spending saw a significant decrease of 31% last year due to completed respiratory trials. This reduction highlights a strategic pivot as the company reassesses its priorities amidst an evolving market landscape.Vertex Pharmaceuticals is making headlines with its ambitious revenue goals outside its established cystic fibrosis franchise. By 2026, Vertex aims to generate $500 million from non-CF medications, with recent launches like Casgevy and Journavx already showing promise by collectively bringing in $175.6 million last year. This diversification strategy is critical for mitigating risks associated with dependence on a single therapeutic area and reflects a broader industry trend towards strategic realignment. Additionally, Vertex remains under close observation within kidney disease portfolios, particularly with Povetacicept—an IgA nephropathy treatment—and the success of Journavx impacting market positions by offering chronic kidney disease patients new therapeutic options.PTC Therapeutics has faced setbacks with its FDA application withdrawal for Translarna, intended for treating nonsense mutation Duchenne muscular dystrophy. The decision came after receiving adverse feedback from the FDA, highlighting the complexities involved in gaining approval for therapies targeting intricate genetic conditions. Such hurdles underscore the high-risk nature of biotech ventures that are heavily reliant on regulatory timelines.Novartis is pushing forward with plans to seek full FDA approval for Vanrafia, its IgA nephropathy drug, despite not meeting primary kidney function goals in Phase 3 trials. This move aligns with a growing trend where companies pursue approval based on secondary endpoints or other supportive data when primary outcomes fall short. Such strategies underscore the competitive and high-stakes environment surrounding drug approval pathways.Novo Nordisk is expanding its production capabilities in Ireland to meet increasing demand for Wegovy, their obesity drug that's seen impressive sales in the U.S. This investment underscores the global potential for obesity treatments and highlights how manufacturing expansions are pivotal to supporting international market entry.In Europe, Amgen has secured approval for Uplizna in treating myasthenia gravis, adding another option to an already crowded treatment landscape but offering patients additional therapeutic choices. Meanwhile, AbbVie has launched a legal challenge against Botox's inclusion in drug pricing negotiations under the Inflation Reduction Act (IRA), arguing it should be excluded due to its plasma-derived nature.Ultragenyx has announced a 10% workforce reduction amid halted gene therapy plans and unsuccessful late-stage trials in brittle bone disease. These adjustments often reflect broader strategic shifts within biopharma companies as they realign focus and resources. Ultragenyx's operational challenges highlight the volatile nature of biotech ventureSupport the show

China's Commerce Ministry announces a tariff of up to 11.7% (prev. 42.7%) on EU dairy products; effective from February 13th.European equities broadly in the green; Financials lead as Schroders (+28.5%) gets acquired by Nuveen; US equity futures are entirely in the green.G10s mostly firmer against the USD; AUD takes a slight breather.Gilts lead after soft GDP though BoE pricing largely unaffected; USTs tread water ahead of Friday's CPI.WTI and Brent trade slightly lower as geopolitics remain quiet; IEA cut 2026 global oil demand growth and nudged lower supply growth forecasts.Looking ahead, highlights include US Weekly/Continuing Claims, Existing Home Sales (Jan), EU Informal Leaders Retreat, Speakers including ECBʼs Lane & Nagel, BoCʼs Rogers, Supply from the US, Earnings from Applied Materials, Arista Networks, Vertex Pharmaceuticals, Howmet Aerospace, Coinbase & American Electric Power.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

On this episode Gil sits with Michael Rosenblatt, MD, one of the most accomplished physician-scientists in modern medicine. He is former Chief Medical Officer of Merck, where he led global scientific strategy and medical affairs. Previously he served as Dean of Tufts University School of Medicine, Chief Scientific Officer at Vertex Pharmaceuticals, and Professor of Medicine at Harvard Medical School, where he advanced groundbreaking research in endocrinology, metabolic bone disease, and translational science. We discuss the intersection of academia, biotechnology, pharmaceutical innovation, and the clinical science shaping modern drug development and the future of precision therapeutics.

This is the 68th episode in my drug pronunciation series. In this episode, I divide Journavx and suzetrigine into syllables, tell you which syllables to emphasize, and share my sources. The written pronunciations are below and in the show notes on https://www.thepharmacistsvoice.com. Special thanks to Kelly Glynn at Vertex Pharmaceuticals for nominating Journavx for this episode.   Note: we don't cover pharmacology in this series. Just pronunciations.   Journavx = jur-NAV-ix jur, like Journey (Bringing Journavx to market was a long journey ~27 years.) NAV, which is the name of the voltage-gated sodium channel that Journavx blocks. Journavx blocks NAV 1.8. ix, like "fix." Emphasize NAV. The written pronunciation came from tweaking the written pronunciation in the Patient Information section of the prescribing information for Journavx (accessed 11-25-2025).  My source for the spoken pronunciation is journavx.com. Click the small *speaker* symbol next to the word "Journavx" on the landing page to hear the pronunciation. As an alternative, listen to the videos on journavx.com and journavxhcp.com (accessed 11-25-25).   Suzetrigine = soo-ZE-tri-jeen soo, as in Journavx soothes pain ZE,  like zest tri, like trigger jeen, like the word "gene" (as in genetic) Emphasize the second syllable, "ZE."  My source for the written pronunciation is the American Medical Association's website. Special thanks to Simran at Vertex Pharmaceuticals Global Medical Information Department for helping me find the written pronunciation!  The spoken pronunciation of suzetrigine can be heard in the MOA video on journavxhcp.com (accessed 11-25-25).   If you know someone who would like to learn how to say Journavx or suzetrigine, please share this episode with them. Subscribe for all future episodes. This podcast is on all major podcast players and YouTube. Popular links are below. ⬇️   Apple Podcasts   https://apple.co/42yqXOG  Spotify  https://spoti.fi/3qAk3uY  Amazon/Audible  https://adbl.co/43tM45P YouTube https://bit.ly/43Rnrjt   ⭐️ Sign up for The Pharmacist's Voice ® monthly email newsletter! https://bit.ly/3AHJIaF   Host Background: Kim Newlove has been an Ohio pharmacist since 2001 (BS Pharm, Chem Minor). Her experience includes hospital, retail, compounding, and behavioral health. She is also an author, voice actor (medical narrator and audiobook narrator), podcast host, and consultant (audio production and podcasting).    Other links from this episode Ohio Pharmacists Association https://www.ohiopharmacists.org Kelly Glynn https://www.linkedin.com/in/kelly-glynn-23208136/  Vertex Pharmaceuticals https://www.vrtx.com/    Other episodes in this series The Pharmacist's Voice Podcast Episode 356, Pronunciation Series Episode 67 (Zanaflex) The Pharmacist's Voice Podcast Episode 352, Pronunciation Series Episode 66 (Yescarta) The Pharmacist's Voice Podcast Episode 350, Pronunciation Series Episode 65 (Xarelto) The Pharmacist's Voice Podcast Episode 349, Pronunciation Series Episode 64 (acetaminophen) The Pharmacist's Voice Podcast Episode 348, Pronunciation Series Episode 63 (Welchol/colesevelam) The Pharmacist's Voice Podcast Episode 346, Pronunciation Series Episode 62 (valacyclovir) The Pharmacist's Voice Podcast Episode 343, Pronunciation Series Episode 61 (ubrogepant) The Pharmacist's Voice Podcast Episode 341, Pronunciation Series Episode 60 (topiramate) The Pharmacist's Voice Podcast Episode 339, Pronunciation Series Episode 59 (Suboxone) The Pharmacist's Voice Podcast Episode 337, Pronunciation Series Episode 58 (rosuvastatin)  The Pharmacist's Voice Podcast Episode 335, Pronunciation Series Episode 57 (QVAR) The Pharmacist's Voice Podcast Episode 333, Pronunciation Series Episode 56 (pantoprazole)  The Pharmacist's Voice Podcast Episode 330, Pronunciation Series Episode 55 (oxcarbazepine) The Pharmacist's Voice Podcast Episode 328, Pronunciation Series Episode 54 (nalmefene) The Pharmacist's Voice Podcast Episode 326, Pronunciation Series Episode 53 (Myrbetriq) The Pharmacist's Voice Podcast Episode 324, Pronunciation Series Episode 52 (liraglutide)  The Pharmacist's Voice Podcast Episode 322, Pronunciation Series Episode 51 (ketamine) The Pharmacist's Voice Podcast Episode 320, Pronunciation Series Episode 50 (Jantoven) The Pharmacist's Voice Podcast Episode 318, Pronunciation Series Episode 49 (ipratropium) The Pharmacist's Voice Podcast Episode 316, Pronunciation Series Episode 48 (hyoscyamine) The Pharmacist's Voice Podcast Episode 313, Pronunciation Series Episode 47 (guaifenesin) The Pharmacist's Voice Podcast Episode 311, Pronunciation Series Episode 46 (fluticasone) The Pharmacist's Voice Podcast Episode 309, Pronunciation Series Episode 45 (empagliflozin) The Pharmacist's Voice Podcast Episode 307, Pronunciation Series Episode 44 (dapagliflozin) The Pharmacist's Voice Podcast Episode 304, Pronunciation Series Episode 43 (cetirizine)  The Pharmacist's Voice Podcast Episode 302, Pronunciation Series Episode 42 (buspirone)  The Pharmacist's Voice Podcast Episode 301, Pronunciation Series Episode 41 (azithromycin) The Pharmacist's Voice Podcast Episode 298, Pronunciation Series Episode 40 (umeclidinium) The Pharmacist's Voice Podcast Episode 296, Pronunciation Series Episode 39 (Januvia)  The Pharmacist's Voice Podcast Episode 294, Pronunciation Series Episode 38 (Yasmin) The Pharmacist's Voice Podcast Episode 292, Pronunciation Series Episode 37 (Xanax, alprazolam) The Pharmacist's Voice Podcast Episode 290, Pronunciation Series Episode 36 (quetiapine)  The Pharmacist's Voice Podcast Episode 287, pronunciation series ep 35 (bupropion) The Pharmacist's Voice Podcast Episode 285, pronunciation series ep 34 (fentanyl) The Pharmacist's Voice Podcast Ep 281, Pronunciation Series Ep 33 levothyroxine (Synthroid) The Pharmacist's Voice ® Podcast Ep 278, Pronunciation Series Ep 32 ondansetron (Zofran) The Pharmacist's Voice ® Podcast Episode 276, pronunciation series episode 31 (tocilizumab-aazg) The Pharmacist's Voice ® Podcast Episode 274, pronunciation series episode 30 (citalopram and escitalopram) The Pharmacist's Voice ® Podcast Episode 272, pronunciation series episode 29 (losartan) The Pharmacist's Voice Podcast Episode 269, pronunciation series episode 28 (tirzepatide) The Pharmacist's Voice Podcast Episode 267, pronunciation series episode 27 (atorvastatin)  The Pharmacist's Voice Podcast Episode 265, pronunciation series episode 26 (omeprazole) The Pharmacist's Voice Podcast Episode 263, pronunciation series episode 25 (PDE-5 inhibitors) The Pharmacist's Voice Podcast Episode 259, pronunciation series episode 24 (ketorolac) The Pharmacist's Voice ® Podcast episode 254, pronunciation series episode 23 (Paxlovid) The Pharmacist's Voice ® Podcast episode 250, pronunciation series episode 22 (metformin/Glucophage) The Pharmacist's Voice Podcast ® episode 245, pronunciation series episode 21 (naltrexone/Vivitrol) The Pharmacist's Voice ® Podcast episode 240, pronunciation series episode 20 (levalbuterol) The Pharmacist's Voice ® Podcast episode 236, pronunciation series episode 19 (phentermine)  The Pharmacist's Voice ® Podcast episode 228, pronunciation series episode 18 (ezetimibe) The Pharmacist's Voice ® Podcast episode 219, pronunciation series episode 17 (semaglutide) The Pharmacist's Voice ® Podcast episode 215, pronunciation series episode 16 (mifepristone and misoprostol) The Pharmacist's Voice ® Podcast episode 211, pronunciation series episode 15 (Humira®) The Pharmacist's Voice ® Podcast episode 202, pronunciation series episode 14 (SMZ-TMP) The Pharmacist's Voice ® Podcast episode 198, pronunciation series episode 13 (carisoprodol) The Pharmacist's Voice ® Podcast episode 194, pronunciation series episode 12 (tianeptine) The Pharmacist's Voice ® Podcast episode 188, pronunciation series episode 11 (insulin icodec)  The Pharmacist's Voice ® Podcast episode 184, pronunciation series episode 10 (phenytoin and isotretinoin) The Pharmacist's Voice ® Podcast episode 180, pronunciation series episode 9 Apretude® (cabotegravir) The Pharmacist's Voice ® Podcast episode 177, pronunciation series episode 8 (metoprolol)  The Pharmacist's Voice ® Podcast episode 164, pronunciation series episode 7 (levetiracetam) The Pharmacist's Voice ® Podcast episode 159, pronunciation series episode 6 (talimogene laherparepvec or T-VEC)  The Pharmacist's Voice ® Podcast episode 155, pronunciation series episode 5 Trulicity® (dulaglutide)  The Pharmacist's Voice ® Podcast episode 148, pronunciation series episode 4 Besponsa® (inotuzumab ozogamicin) The Pharmacist's Voice ® Podcast episode 142, pronunciation series episode 3 Zolmitriptan and Zokinvy The Pharmacist's Voice ® Podcast episode 138, pronunciation series episode 2 Molnupiravir and Taltz The Pharmacist's Voice ® Podcast episode 134, pronunciation series episode 1 Eszopiclone and Qulipta   Kim's websites and social media links: ✅ Guest Application Form (The Pharmacist's Voice Podcast) https://bit.ly/41iGogX ✅ Monthly email newsletter sign-up link https://bit.ly/3AHJIaF  ✅ LinkedIn Newsletter link https://bit.ly/40VmV5B ✅ Business website https://www.thepharmacistsvoice.com ✅ Get my FREE eBook and audiobook about podcasting ✅ The Pharmacist's Voice ® Podcast https://www.thepharmacistsvoice.com/podcast ✅ Drug pronunciation course https://www.kimnewlove.com  ✅ Podcasting course https://www.kimnewlove.com/podcasting  ✅ LinkedIn https://www.linkedin.com/in/kimnewlove ✅ Facebook https://www.facebook.com/kim.newlove.96 ✅ Twitter https://twitter.com/KimNewloveVO ✅ Instagram https://www.instagram.com/kimnewlovevo/ ✅ YouTube https://www.youtube.com/channel/UCA3UyhNBi9CCqIMP8t1wRZQ ✅ ACX (Audiobook Narrator Profile) https://www.acx.com/narrator?p=A10FSORRTANJ4Z ✅ Start a podcast with the same coach who helped me get started (Dave Jackson from The School of Podcasting)! **Affiliate Link - NEW 9-8-23**      Thank you for listening to episode 358 of The Pharmacist's Voice ® Podcast.  If you know someone who would like this episode, please share it with them!

As millions of Americans hit the road to visit family for Thanksgiving, many will pass through, or return to, rural communities. Nearly 60 million Americans live in these areas, yet many struggle to access even basic healthcare as rural hospitals close at record rates.Dr. Jennifer Schneider, co-founder and CEO of Homeward Health, is tackling this crisis head-on by reimagining how care is delivered to Medicare Advantage members in rural America. Drawing on her experiences as a physician, a patient with Type 1 diabetes, and the former president of Livongo, Jenny shares why rural healthcare is both a massive challenge and an untapped opportunity.We cover:

If you've ever been part of the cystic fibrosis community, you've probably heard of the sweat chloride test, maybe you've even had one yourself. But what does that test really measure, and why does it still matter in the age of CF modulators?Laura talks with Dr. Patrick Sosnay, Vice President and Head of CF Development at Vertex Pharmaceuticals. Before joining Vertex, Dr. Sosnay was a clinician and researcher at Johns Hopkins, where he helped define the genetic criteria for diagnosing CF and co-founded the influential CFTR2 database.Dr. Sosnay brings his expertise, and a gift for explaining complex science.  He unpacks the real story behind sweat chloride testing. Together, we explore:* What the sweat test actually measures — and how it connects to the CFTR protein.* Why sweat chloride is still vital long after diagnosis.* How researchers use it to track CF progression and measure treatment success.* What all this means for people living with CF and their families today.This episode redefines the sweat chloride test as more than just a diagnostic number, it's a powerful marker of health, innovation, and hope for the future.Listen now and gain a fresh perspective on one of the most familiar, yet evolving  parts of cystic fibrosis care.(Vertex is a sponsor of this podcast. The Bonnell Foundation remains committed to transparent, balanced conversations that serve the CF community first.)Additionaly we explore:What the sweat test measures and how it's tied to the CFTR protein (cystic fibrosis transmembrane conductance regulator).Why sweat chloride remains important well beyond diagnosis.How researchers use it to understand CF progression and evaluate new treatments.What this means for families and patients living with CF every day.This episode shares the reframing of the sweat chloride test, not as a simple number, but as a meaningful marker of health, research, and hope for the future. Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Novo Nordisk's drug Wegovy has successfully reduced cardiovascular risk by 57% compared to tirzepatide. Eli Lilly has terminated two mid-stage trials for a second obesity asset, while Vertex Pharmaceuticals and Enlaza Therapeutics have formed a potential $2 billion partnership to develop drugs for autoimmune diseases. Biogen and Eisai have received FDA approval for the subcutaneous maintenance formulation of Leqvembi. Arrowhead Pharmaceuticals has secured a commitment of up to $2 billion from Novartis for an siRNA Parkinson's program. The FDA's new radiopharma guidance is expected to accelerate the space, and Teva has launched the first generic version of Novo Nordisk's obesity drug Saxenda. The pharmaceutical industry is navigating uncertainty during turbulent times, with companies focusing on innovation and new partnerships to drive progress.The FDA has issued new radiopharma guidance, which former FDA Commissioner Stephen Hahn believes is crucial for cancer therapy. Despite recent investments in radiopharmaceutical therapeutics by big pharma, the FDA's approval of updated COVID-19 vaccines with restrictions contradicts the medical freedom promised by health secretary Robert F. Kennedy Jr. Rare diseases secured four FDA firsts in August, including a win for Novo Nordisk's glp-1 drug WeGovy. Investment in new ALS therapies signals progress after setbacks, with new biotechs and collaborative initiatives showing promise at Bio2025. Other news includes the closure of Appia, Senate summons of Kennedy, updates on COVID-19 vaccines, and Lilly's obesity pill heading to the FDA. Thank you for listening to Pharma and Biotech daily.

“I always say that singing and performing was as much a part of my DNA as cystic fibrosis.” Julia RaeFrom the moment Julia Rae could speak, she was singing, and from the moment she could dream, she was already imagining a bigger stage. As her mother fondly recalls, at just two years old, Julia was watching Barney on TV and asked, “How do I get in there and do that with him?” That instinct, that pull toward performance, was never just about the spotlight. For Julia Rae, the stage became her sanctuary, and later, her platform for purpose.Diagnosed with cystic fibrosis at birth, Julia's life has never followed an easy script. But instead of letting a chronic illness limit her, she embraced the full range of her voice, as a singer, actress, writer, and advocate. She didn't just want to perform; she wanted to make a difference.At 16, Julia founded Singing at the Top of My Lungs, a nonprofit inspired by her own hospital experiences. Initially, the organization supported both CF research and creative therapies at children's hospitals. But as larger institutions took a stronger lead in research, Julia saw a growing gap elsewhere.“I've decided to devote all of Singing at the Top of My Lungs to music and creative art therapies... They are significantly underfunded, not covered by insurance, and they are often, honestly, the unsung heroes of children's hospitals.”Julia's foundation now champions music and art therapies — the very programs that once transformed her own stays in sterile hospital rooms into spaces of joy and creativity. She knows firsthand that healing isn't just about medicine — it's also about expression, play, and being seen as more than your diagnosis.Her own career blossomed when a YouTube performance caught the attention of a Beverly Hills record producer, leading to her single “Be That Girl” being featured in the film The Greening of Whitney Brown. She's since performed the national anthem at major sports arenas, starred in national commercials, and most recently, in the 2024 film Playing Through. Her appearance on ABC's Listen to Your Heart introduced her to a national audience, but she never let fame outshine her mission.In parallel with her artistic pursuits, Julia has become a tireless advocate. She co-created and hosted Making It Matterwith the Boomer Esiason Foundation, currently leads Uncommon Lungs with Vertex Pharmaceuticals, and recently launched a podcast called A Deeper Look, spotlighting bold, thoughtful conversations with inspiring women.Julia Rae is more than a performer, she's a force. Her life is a testament to what happens when passion meets purpose, and when a voice refuses to be silenced by circumstance.For the chronic illness community, and for anyone who's ever been told “you can't” — Julia's story sings a different tune.She's not just making music. She's making it matter. Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

Learn why culture and constant innovation are essential to developing life-changing biopharma treatments. Vertex Pharmaceuticals focuses on “serial innovation” because this year's billion-dollar blockbuster drug could become next year's failure. How does this biopharmaceutical company recruit and onboard employees, and how does it create a culture where the best ideas thrive? Join David Young and guest Reshma Kewalramani, president and CEO at Vertex Pharmaceuticals and a recipient of the 2025 CED Distinguished Leadership Awards. You'll learn about Kewalramani's career path, what the company learned from developing a hepatitis C drug, and why the company welcomes in students to experiment alongside employees. The Leadership in Challenging Times discussions feature timely and insightful discussions with the outstanding CEOs who are recipients of CED's Distinguished Leadership Awards. Business leader honorees discuss the unprecedented challenges facing the nation and how they are helping chart a path forward for both their companies and communities in which they operate. For more from The Conference Board: ·         CED Announces Recipients of Its 2025 Distinguished Leadership Awards ·         CED Distinguished Leadership Awards Celebration ·         Women in STEM: Closing the Gender Gap

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: loads of news from American Diabetes Association Scientific Sessions, GLP1 for T1D, Tech updates, diabetes in space, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Top story – looking back at The American Diabetes Association Scientific Sessions conference. I won't recap everything here – but I'll link up to a few more comprehensive article. Here's just a taste! XX A single infusion of a new stem cell-based treatment helped 10 out of 12 people with severe type 1 diabetes stop using insulin, researchers report. The treatment, called zimislecel, was made by Vertex Pharmaceuticals. It's an infusion of lab-grown islet cells. A year after getting the therapy, 10 patients no longer needed insulin shots. The other two were able to reduce how much insulin they needed.  The treatment requires patients to take immunosuppressive drugs, which may raise the risk of infections or cancer in the long run, experts said. https://www.usnews.com/news/health-news/articles/2025-06-24/stem-cell-treatment-may-free-some-with-type-1-diabetes-from-insulin XX New study shows inhaled insulin is safe and effective for children with type 1 diabetes. This is Mannkind's Afrezza, which takes the place of rapid-acting mealtime insulin. Findings indicate that inhaled insulin delivers glycemic control comparable to injected rapid-acting insulin. Inhaled insulin was also associated with less weight gain and slightly higher patient and parent preference scores. These findings add to outcomes shared from INHALE 1 late last year. Based on the findings of the inhaled insulin study, MannKind looks to seek FDA approval to expand Afrezza's indication to children. The company also aims to evaluate inhaled insulin at diagnosis and in automated insulin delivery systems in additional studies. https://www.drugdeliverybusiness.com/study-mannkind-inhaled-insulin-safe-effective-children/ XX Positive outcomes in two different studies looking at GLP 1 medications for type 1. Semaglutide – brand name Ozempic or Wegovy - reduced glucose levels and weight among patients with type 1 diabetes and obesity. 26-week, double-blind trial of 72 adults, those taking Ozempic spent More than 70% time spent in sensor glucose range (70-180 mg/dL) Less than 4% time spent in hypoglycemia (

Broadcast from KSQD, Santa Cruz on 6-26-2025: Dr. Dawn opens with groundbreaking results from Vertex Pharmaceuticals' stem cell treatment for severe type 1 diabetes. The experimental therapy, Zimislecel, converts stem cells into pancreatic islet cells and infuses them into patients. In a 12-person study, 10 patients no longer need insulin after one year. The cells migrated to the liver and began producing insulin in response to glucose levels. Patients with hypoglycemic unawareness saw complete elimination of dangerous episodes after three months. However, patients must take lifelong immunosuppressive drugs to prevent rejection. The research represents 25 years of work by Harvard's Doug Melton. A caller asks about Keytruda treatment for melanoma. Dr. Dawn explains it's an immunotherapy drug targeting programmed death receptors that cancer cells hijack to evade immune response. The drug can cause serious immune overreactions but is standard for metastatic melanoma. Treatment protocols depend on cancer staging. For young patients with decades to lose, aggressive treatment is often justified despite risks. An email about morning arthritis pain leads to chronotherapy research discussion. Macrophages have energy levels that peak in the morning when inflammasome activation is quicker and more robust, explaining why arthritis pain is worst after overnight rest. Treatment timing could optimize anti-inflammatory medications by taking them at bedtime. Another email about eye irritation prompts diagnostic discussion. Dr. Dawn recommends examining for bacterial blepharitis before assuming food allergies and testing antihistamine drops. For elimination diets, common allergens include wheat, dairy, corn, soy, and peanuts. However, without other symptoms, food allergies are unlikely causes of isolated eye problems. Dr. Dawn explores advancing CAR-T cell therapy using RNA technology. Traditional therapy costs up to $500,000 per patient requiring lab reprogramming. New RNA-containing nanoparticles temporarily create antigen receptors for about one week. Mouse studies eliminated detectable tumors at highest doses. While effects are temporary, this could dramatically reduce costs and complexity. She discusses DNA forensics evolution from O.J. trial era to current technologies. New paleogenomics technology can analyze fragmented DNA from hair, previously considered unusable. Mitochondrial DNA analysis can definitively exonerate suspects. This led to Charles Fane's release after 17 years on death row when hair evidence proved innocence and identified the actual perpetrator. Dr. Dawn introduces Barrett's esophagus screening replacing invasive endoscopy. Patients swallow a capsule containing a compressed sponge that expands in the stomach and is pulled out via string, collecting esophageal cells. The test identifies abnormalities with 100-fold increased cancer risk when positive and 98% accuracy when negative, allowing targeted endoscopy only for high-risk patients. She concludes discussing body composition analysis superiority over BMI. Studies found overweight BMI showed 3.6 times higher heart disease risk, while large waist circumference showed four times higher risk. However, BMI had no significant relationship with overall mortality. Dr. Dawn advocates for bioimpedance analysis devices to measure body fat percentage and track muscle loss.

Broadcast from KSQD, Santa Cruz on 6-26-2025: Dr. Dawn opens with groundbreaking results from Vertex Pharmaceuticals' stem cell treatment for severe type 1 diabetes. The experimental therapy, Zimislecel, converts stem cells into pancreatic islet cells and infuses them into patients. In a 12-person study, 10 patients no longer need insulin after one year. The cells migrated to the liver and began producing insulin in response to glucose levels. Patients with hypoglycemic unawareness saw complete elimination of dangerous episodes after three months. However, patients must take lifelong immunosuppressive drugs to prevent rejection. The research represents 25 years of work by Harvard's Doug Melton. A caller asks about Keytruda treatment for melanoma. Dr. Dawn explains it's an immunotherapy drug targeting programmed death receptors that cancer cells hijack to evade immune response. The drug can cause serious immune overreactions but is standard for metastatic melanoma. Treatment protocols depend on cancer staging. For young patients with decades to lose, aggressive treatment is often justified despite risks. An email about morning arthritis pain leads to chronotherapy research discussion. Macrophages have energy levels that peak in the morning when inflammasome activation is quicker and more robust, explaining why arthritis pain is worst after overnight rest. Treatment timing could optimize anti-inflammatory medications by taking them at bedtime. Another email about eye irritation prompts diagnostic discussion. Dr. Dawn recommends examining for bacterial blepharitis before assuming food allergies and testing antihistamine drops. For elimination diets, common allergens include wheat, dairy, corn, soy, and peanuts. However, without other symptoms, food allergies are unlikely causes of isolated eye problems. Dr. Dawn explores advancing CAR-T cell therapy using RNA technology. Traditional therapy costs up to $500,000 per patient requiring lab reprogramming. New RNA-containing nanoparticles temporarily create antigen receptors for about one week. Mouse studies eliminated detectable tumors at highest doses. While effects are temporary, this could dramatically reduce costs and complexity. She discusses DNA forensics evolution from O.J. trial era to current technologies. New paleogenomics technology can analyze fragmented DNA from hair, previously considered unusable. Mitochondrial DNA analysis can definitively exonerate suspects. This led to Charles Fane's release after 17 years on death row when hair evidence proved innocence and identified the actual perpetrator. Dr. Dawn introduces Barrett's esophagus screening replacing invasive endoscopy. Patients swallow a capsule containing a compressed sponge that expands in the stomach and is pulled out via string, collecting esophageal cells. The test identifies abnormalities with 100-fold increased cancer risk when positive and 98% accuracy when negative, allowing targeted endoscopy only for high-risk patients. She concludes discussing body composition analysis superiority over BMI. Studies found overweight BMI showed 3.6 times higher heart disease risk, while large waist circumference showed four times higher risk. However, BMI had no significant relationship with overall mortality. Dr. Dawn advocates for bioimpedance analysis devices to measure body fat percentage and track muscle loss.

Damian Sanchez, (Damian J to music fans) is a Miami-based jazz musician. A car accident landed him in the hospital with multiple fractures to his leg. Once there, he faced the difficult decision of whether or not to take the pain medication that was offered to him. With patients like Damian in mind, Dr. Paul Negulescu and the research team at Vertex are thinking differently about pain – they’re investigating potential non-opioid based treatment options that aim to target pain differently. This episode of Targeting the Toughest Diseases is sponsored by Vertex Pharmaceuticals.See omnystudio.com/listener for privacy information.

In der heutigen Folge von „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Daniel Eckert über die Magie der Mausaktie Disney, Insolvenz einer Diät-Ikone und den stoischen Kurs der Fed. Außerdem geht es um Alphabet, Nvidia, Uber, Charles River Laboratories, Hensoldt, Fresenius, Vonovia, Carl Zeiss Meditec, Eli Lilly, Novo Nordisk, WeightWatchers, Volkswagen, Mercedes, BMW, Ferrari, Nvidia, Meta Platforms, Microsoft, Altria, Saudi-Aramco, AppLovin, ConocoPhillips, CNOOC, Investor AB, Arista Networks, Visa, Blackstone, KKR, Pinduoduo, Investor AB, Hermès, Münchener Rück, Allianz, Deutsche Telekom, SAP, MicroStrategy und Vertex Pharmaceuticals. Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Market volatility is starting to decrease, and markets are returning to a more normal state. The short-term picture is slowly moving into overbought territory, while both the medium- and long-term outlooks are still flashing strong buy signals.On Wednesday, the Fed and Chair Powell will announce the interest rate decision, with markets widely anticipating no change.Throughout the week, several high-profile companies will report their quarterly results, including Palantir, AMD, Vertex Pharmaceuticals, Disney, Uber, Shopify, and others.All this and more in this week's "Trading Tips With Jim."#StockMarket #MarketUpdate #TradingTips #Investing #StockAnalysis #Palantir #AMD #VertexPharmaceuticals #Disney #Uber #Shopify #EarningsSeason #FederalReserve #Powell #InterestRates #BuySignals #MarketOutlook

In this episode, Mark Longo, Henry Schwartz (Cboe) and Mike Tosaw (St. Charles Wealth Management) hosts delve into current market trends, unusual options activity, and listener questions. They discuss VIX movement, the resurgence of gold, and controversial trades ahead of the tariff announcement. New options products, such as the S&P Equal Weighted 500 Index options, are introduced, and there's an examination of activity in Vertex Pharmaceuticals, NeoGenomics, Eldorado Gold Corp, and Dynatrace. The hosts also review audience poll results on zero-day options trading and the viability of certain puts in Apple and Nvidia. 00:00 Introduction to Options Insider Radio Network 01:18 Meet the Hosts and Sponsors 03:16 Market Overview and Trading Block 05:41 Volatility and Market Trends 13:13 Gold and Precious Metals Discussion 15:43 Options Market Activity 30:55 Unusual Options Activity in Vertex Pharmaceuticals 33:48 Biotech and Option Flow Insights 34:51 NeoGenomics Inc: A Rough Year 37:21 Gold's Impressive Run 43:13 Dynatrace Inc: Tech Observability 47:01 Mail Block: Listener Questions 57:56 Around the Block: Market Watch  

In this episode, Mark Longo, Henry Schwartz (Cboe) and Mike Tosaw (St. Charles Wealth Management) hosts delve into current market trends, unusual options activity, and listener questions. They discuss VIX movement, the resurgence of gold, and controversial trades ahead of the tariff announcement. New options products, such as the S&P Equal Weighted 500 Index options, are introduced, and there's an examination of activity in Vertex Pharmaceuticals, NeoGenomics, Eldorado Gold Corp, and Dynatrace. The hosts also review audience poll results on zero-day options trading and the viability of certain puts in Apple and Nvidia. 00:00 Introduction to Options Insider Radio Network 01:18 Meet the Hosts and Sponsors 03:16 Market Overview and Trading Block 05:41 Volatility and Market Trends 13:13 Gold and Precious Metals Discussion 15:43 Options Market Activity 30:55 Unusual Options Activity in Vertex Pharmaceuticals 33:48 Biotech and Option Flow Insights 34:51 NeoGenomics Inc: A Rough Year 37:21 Gold's Impressive Run 43:13 Dynatrace Inc: Tech Observability 47:01 Mail Block: Listener Questions 57:56 Around the Block: Market Watch  

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/YKX865. CME/NCPD credit will be available until April 18, 2026.Innovation Takes Shape in SCD: Rewriting Management Principles With Gene Therapy and Revisiting the Role of HCT In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/YKX865. CME/NCPD credit will be available until April 18, 2026.Innovation Takes Shape in SCD: Rewriting Management Principles With Gene Therapy and Revisiting the Role of HCT In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/YKX865. CME/NCPD credit will be available until April 18, 2026.Innovation Takes Shape in SCD: Rewriting Management Principles With Gene Therapy and Revisiting the Role of HCT In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/YKX865. CME/NCPD credit will be available until April 18, 2026.Innovation Takes Shape in SCD: Rewriting Management Principles With Gene Therapy and Revisiting the Role of HCT In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/YKX865. CME/NCPD credit will be available until April 18, 2026.Innovation Takes Shape in SCD: Rewriting Management Principles With Gene Therapy and Revisiting the Role of HCT In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/YKX865. CME/NCPD credit will be available until April 18, 2026.Innovation Takes Shape in SCD: Rewriting Management Principles With Gene Therapy and Revisiting the Role of HCT In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Vertex Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

Fund your account in five minutes or less at https://www.public.com/CSI and get up to $10,000 when you transfer your old portfolio. Join us on Discord with Semiconductor Insider: https://ko-fi.com/chipstockinvestor/tiersIn this episode of Chip Stock Investor, Kasey discusses Vertex Pharmaceuticals which was a recent addition to the Chip Stock Investor portfolio. Vertex had two new approvals before the most recent earnings report with more to come in the coming years. Will 2025 be a breakout year for Vertex?Supercharge your analysis with AI! Get 15% of your membership with our special link here: https://finchat.io/csi/Affiliate links that are sprinkled in throughout this video. If something catches your eye and you decide to buy it, we might earn a little coffee money. Thanks for helping us (Kasey) fuel our caffeine addiction!Content in this video is for general information or entertainment only and is not specific or individual investment advice. Forecasts and information presented may not develop as predicted and there is no guarantee any strategies presented will be successful. All investing involves risk, and you could lose some or all of your principal. #vertexstock #vrtx #newpainmedication #pharmastocks #healthcarestocks #semiconductors #chips #investing #stocks #finance #financeeducation #financeeducation #finance #stocks #investing #investor #financeeducation #stockmarket #chipstockinvestor #semiconductorstocks Nick and Kasey own shares of Vertex PharmaceuticalsPublic Disclosure:All investing involves the risk of loss, including loss of principal. Brokerage services for US-listed, registered securities, options and bonds in a self-directed account are offered by Public Investing, Inc., member FINRA & SIPC. Public Investing offers a High-Yield Cash Account where funds from this account are automatically deposited into partner banks where they earn interest and are eligible for FDIC insurance; Public Investing is not a bank. Cryptocurrency trading services are offered by Bakkt Crypto Solutions, LLC (NMLS ID 1890144), which is licensed to engage in virtual currency business activity by the NYSDFS. Cryptocurrency is highly speculative, involves a high degree of risk, and has the potential for loss of the entire amount of an investment. Cryptocurrency holdings are not protected by the FDIC or SIPC. A Bond Account is a self-directed brokerage account with Public Investing, member FINRA/SIPC. Deposits into this account are used to purchase 10 investment-grade and high-yield bonds. The 6%+ yield is the average, annualized yield to worst (YTW) across all ten bonds in the Bond Account, before fees, as of 12/13/2024. A bond's yield is a function of its market price, which can fluctuate; therefore, a bond's YTW is not “locked in” until the bond is purchased, and your yield at time of purchase may be different from the yield shown here. The “locked in” YTW is not guaranteed; you may receive less than the YTW of the bonds in the Bond Account if you sell any of the bonds before maturity or if the issuer defaults on the bond. Public Investing charges a markup on each bond trade. See our Fee Schedule. Bond Accounts are not recommendations of individual bonds or default allocations. The bonds in the Bond Account have not been selected based on your needs or risk profile. See Bond Account Disclosures to learn more.Alpha is an AI research tool powered by GPT-4. Alpha is experimental and may generate inaccurate responses. Output from Alpha should not be construed as investment research or recommendations, and should not serve as the basis for any investment decision. Public makes no warranties about its accuracy, completeness, quality, or timeliness of any Alpha out. Please independently evaluate and verify any such output for your own use case.*Terms and Conditions apply.

It's the first FDA approval for a pain medication in 25 years. How does the drug work, and who is it for? Also, non-mixing layers of water and hydrocarbons thousands of miles deep could explain the icy planets' strange magnetic fields.The FDA Approves A New, Non-Opioid PainkillerIn January, the Food and Drug Administration approved a new pain medicine called Journavx (suzetrigine), made by Vertex Pharmaceuticals. It's the first time in 25 years the agency has given the green light to a new painkiller. Notably, it's not an opioid and, according to the company, it's not addictive. Unlike opioids, which act directly on the brain, Journavx instead blocks nerve endings across the body that transmit pain.Host Ira Flatow is joined by Dr. Sean Mackey, a professor of anaesthesiology and pain medicine at Stanford University and chief of the Division of Stanford Pain Medicine, to discuss how the new drug works, who should take it, and what its limitations are.Might Uranus And Neptune Have Deep, Multi-Layer Oceans?We've got a pretty good idea about what's beneath the surface of our nearest planetary neighbors, like Mars. But as you get farther out into the solar system, our knowledge becomes scarce. For instance, what's inside the so-called ice giants, Neptune and Uranus?Recent research based on computer simulations of fluids hints that the planets could contain vast multi-layered oceans, as much as thousands of miles deep. A layer of water that is on top of—but doesn't mix with—a deeper layer of hydrocarbons could help explain strange magnetic fields observed during the Voyager mission.Dr. Burkhardt Militzer, a professor of earth and planetary sciences at UC Berkeley, wrote about this idea in the Proceedings of the National Academy of Sciences. He joins Host Ira Flatow to explain his theories.Transcripts for each segment will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Moderate—but not excessive—exercise can curb appetite; When you're older does your ability to absorb supplements decline? FDA warns against eye drop to change eye color; Are soy supplements safe for breast cancer patients? Most ditch GLP-1 drugs after one year; Some B-complex supplements don't deliver full suite of B vitamins; Novel non-addictive pain drug approved; Why mosquitoes can bite in mid-winter; Oops—surgeon removes patient's liver, mistaking it for spleen. 

Today's coverage kicks off with a market panel featuring Barbara Doran of BD8 Capital Partners and Phil Camporeale of J.P. Morgan Asset Management. Earnings highlights include RH, Broadcom, and Costco, with expert analysis from Bernstein's Stacy Rasgon on Broadcom and DA Davidson's Michael Baker on Costco. Globalstar CEO Paul Jacobs discusses investor day developments and reports of Apple Watch integration. Our Angelica Peebles reports on Vertex Pharmaceuticals' non-opioid pain medication and its potential market impact.

In the fifth Season of the National Institute of Neurological Disorders and Stroke's Building Up the Nerve podcast, we help you strengthen your science communication skills with tools and advice to use throughout your career. We know that navigating your career can be daunting, but we're here to help—it's our job!In the sixth episode of the season, we talk about Writing Impactful Publications, focusing on how to structure and write a paper, choose a journal, and craft engaging and accessible figures.Featuring Bang Wong, MA, MS, Senior Director at Vertex Pharmaceuticals; Marina Picciotto, PhD, Professor at Yale University; and Tanya Garcia, PhD, Associate Professor at University of North Carolina, Chapel Hill.ResourcesReferenced paper by Dr. Amy Arnsten: Wang, Min, et al. "α2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex." Cell 129.2 (2007): 397-410. https://www.cell.com/fulltext/S0092-8674(07)00344-3?large_figure=true Referenced Papers by Bang Wong:Wong, B. Design of data figures. Nat Methods 7, 665 (2010). https://doi.org/10.1038/nmeth0910-665 Wong, B. Color coding. Nat Methods 7, 573 (2010). https://doi.org/10.1038/nmeth0810-573Wong, B. Points of view: Color blindness. Nat Methods 8, 441 (2011). https://doi.org/10.1038/nmeth.1618Check out more of Bang's papers: https://www.nature.com/search?author=Bang%20WongColor Contract website:Example: https://webaim.org/resources/contrastchecker/Writing Science: How to Write Papers That Get Cited and Proposals That Get Funded. By Joshua Schimel: https://global.oup.com/academic/product/writing-science-9780199760244 Experimental Design Editorials in the Journal of Neuroscience https://www.jneurosci.org/collection/experimental-design-editorialsTranscript available at http://ninds.buzzsprout.com/.

On today's episode of The Big Podcast, NBA legends reunite as we welcome basketball legend and kidney health advocate, Alonzo Mourning, to the show. Between Shaq and ‘Zo's battles on the court, their contrasting lifestyles (wait until you hear about ‘Zo's diet vs. Shaq's!), and other stories from back in the day, these two legends have plenty to laugh about. But it's not all jokes—Alonzo shares his powerful journey with APOL1-mediated kidney disease (AMKD) and his mission with Power Forward (www.PowerForwardTogether.com) to educate others about this rapidly progressive kidney disease. Tune in for an inspiring conversation and some classic Shaq-and-'Zo banter you don't want to miss!This episode is sponsored by Vertex Pharmaceuticals Incorporated. Alonzo Mourning is a paid spokesperson for Vertex Pharmaceuticals.Don't miss out on all the action this week at DraftKings! Download the DraftKings app today! Sign-up using https://dkng.co/ogs or through my promo code BIGPODZipRecruiter. The smartest way to hire. Go to this exclusive web address to try ZipRecruiter for FREE: http://ZipRecruiter.com/BIGDownload the Gametime app today or http://Gametime.co for $20 off your first order with code BIGPODBuy Liquid Death With Free Shipping on Amazon or http://liquiddeath.com/BIGPODWant to bite Shaq's head off? Get some Shaq-A-Licious at your local Walmart!Subscribe to The Big Podcast YouTube Channel to watch more episodes!Follow us on all platforms: https://linktr.ee/bigpodcast00:00 Intro02:18 Zo saved Shaq in the Finals?06:18 In memory of Dikembe Mutombo12:15 DK segment14:00 DK ad15:10 VRTX ad16:20 Lack of rivalries in current NBA19:05 Today's Big Men23:12 Gametime ad24:25 Liquid Death ad25:40 Alonzo opens up on forced retirement37:00 How Zo takes care of his health53:00 Shaq vs Heat Culture56:44 Being teammates with Shaq59:12 What current players could've handled their era?01:01:10 Zo reviews Shaq's diet and lifestyle01:05:35 Shaqalicious segment01:10:17 Vince Carter dunk01:13:09 Bench meme01:16:07 EndingGAMBLING PROBLEM? CALL 1-800-GAMBLER, (800) 327-5050 or visit gamblinghelplinema.org (MA). Call 877-8-HOPENY/text HOPENY (467369) (NY).Please Gamble Responsibly. 888-789-7777/visit ccpg.org (CT), or visit www.mdgamblinghelp.org (MD).21+ and present in most states. (18+ DC/KY/NH/WY). Void in ONT/OR/NH. Eligibility restrictions apply. On behalf of Boot Hill Casino & Resort (KS).1 per new customer. Min. $5 deposit. Min. $5 bet. Max. $150 issued as non-withdrawable Bonus Bets if your bet wins. Bonus Bets expire in 7 days (168 hours). Stake removed from payout. Terms: dkng.co/dk-offer-terms. Ends 1/5/25 at 11:59 PM ET. Sponsored by DK.MB01RGAXHH8FSSS#nba #lakers #shaq #bigpod #basketball #bigshaq #bigpodcast #alonzomorning Hosted on Acast. See acast.com/privacy for more information.

In this episode, we hear the story of Vertex Pharmaceuticals, and it's a great one. Because their story is a people story. They've undergone tremendous transformation you might call Digital Transformation, but "digital" is a means to an end. At Vertex, transformation serves to amplify their tremendous culture and create talent velocity throughout the organization. Tune in to hear Kimberly Rose, Executive Director of People Experience, Analytics, and Digital Innovation in Human Resources ---- if a title doesn't illustrate the literal evolution of HR, we don't know what does. Kim shares how onboarding, career navigation, and managing people are all grounded in LISTENING TO PEOPLE at Vertex, and she reminds us one size does not fit all when it comes to employee experience.

Last month the FDA approved a new treatment for sickle cell disease, the first medical therapy to use CRISPR gene editing technology. It works by identifying the gene or genes causing the disorder, modifying those genes and then returning them to the patient's body.There are now two gene therapies offered by pharmaceutical companies for sickle cell disease: Casgevy from Vertex Pharmaceuticals and CRISPR Therapeutics, and Lyfgenia from BlueBird Bio. But prices for these one-time treatments are steep: Casgevy costs $2.2 million per patient and Lyfgenia $3.1 million.Both promise a full cure, which would be life-changing for patients with this debilitating condition. Over 100,000 Americans, mostly of African descent, have sickle cell disease.This milestone raises more questions: What will be the next disease that CRISPR can help cure? And is it possible to reduce the costs of gene therapy treatments?Ira talks with Dr. Fyodor Urnov, professor of molecular and cell biology and scientific director of technology and translation at the Innovative Genomics Institute, based at the University of California, Berkeley, about the future of CRISPR-based cures.Transcripts for this segment will be available the week after the show airs on sciencefriday.com. To stay updated on all things science, sign up for Science Friday's newsletters.